



Ref: SEC/SE/2026-27

June 11, 2026

To,
Corporate Relations Department
BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai- 400001

Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor
Plot No. C/1, G Block, Bandra Kurla Complex
Bandra (E), Mumbai – 400051

BSE Scrip Code: 500096

NSE Scrip Symbol: DABUR

Sub: Submission of information under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

In continuation of our letter dated June 1, 2026 and pursuant to provisions of Regulation 30 read with sub-para 20 of Para A of Part A of Schedule III of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 ("Listing Regulations") read with SEBI master circular no. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 issued on July 11, 2023 (last updated on January 30, 2026), please find below details related to action(s) taken or order(s) passed:

1	Name of the authority	United States Food & Drug Administration ("US FDA")
2	Nature and details of the action(s) taken or order(s) passed	<p>US FDA had inspected Company's manufacturing plant situated at Silvassa, Dadra and Nagar Haveli and had identified certain deficiencies on account of data integrity and maintenance lapses.</p> <p>Upon conclusion of the inspection, the Company had received inspectional observations to which responses were suitably submitted to US FDA.</p> <p>Now, pursuant to observations noted by the authority, review of the Company's responses and Establishment Inspection Report (EIR), US FDA has issued an Import Alert (IA) 66-40 on June 10, 2026, for drugs manufactured by the Company at the aforesaid plant.</p>
3	Date of receipt of direction or order, including any ad interim or interim orders, or any other communication from the authority	June 10, 2026
4	Details of the violation(s)/contravention(s) committed or alleged to be committed	There is no violation(s)/contravention(s) committed or alleged to be committed.
5	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	<p>There is no impact on financial, operation or other activities of the Company due to this order. The order concerns to only a small part of our manufacturing plant situated at Silvassa, Dadra and Nagar Haveli, in relation to private label products, which generates insignificant revenue for the Company. Domestic products are not covered and not impacted by this order. The aforesaid plant continues to be operational.</p> <p>We are continuing to engage with the US FDA authority by providing corrective and preventive action plans along with proactive and strong action on the ground to fix the identified gaps. In addition, multiple internal and external independent third party testing has shown no out of specification or any other concerns with any of Company's products. We remain committed to product quality and consumer safety despite this</p>



		one-off incident. We operate sites across the globe and are taking effective action to implement alternate sourcing strategies for our US customers.
6	Explanation for delay in disclosure	There is no material delay on the part of the Company as the Company was reviewing the Order and evaluating next steps in the matter.

The above information was received by the Company on June 10, 2026 at 3.29 a.m. The above information shall also be made available on the Company's website at www.dabur.com.

This is for your kind information and records.

Thanking You,
Yours faithfully,
For **Dabur India Limited**

(Ashok Kumar Jain)
Group Company Secretary and Chief Compliance Officer

